Database→Hexarelin
Tier 2-3GH SecretagogueCardiacBody CompositionPREMIUM

Hexarelin

Hexarelin (Examorelin) -- Synthetic GHS-R1a and CD36 Agonist Hexapeptide
Not FDA-approved for any therapeutic indication. Not approved by EMA or any other major regulatory authority. Developed by Mediolanum Farmaceutici (Italy) and reached Phase 2 clinical trials for GH deficiency and congestive heart failure; development discontinued in 2005 for commercial/strategic reasons rather than safety failure. Not on compounding pharmacy approved lists. WADA Prohibited List S2.2: GH-Releasing Peptides, explicitly named as examorelin (hexarelin); prohibited at all times.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Hexarelin (examorelin) is a synthetic hexapeptide GH secretagogue developed by Mediolanum Farmaceutici. It is the most potent traditional GHRP for acute GH release -- exceeding maximal GHRH -- and uniquely binds both GHS-R1a and cardiac CD36 receptors. Three human cardiac studies demonstrate acute GH-independent improvements in left ventricular ejection fraction in healthy volunteers (n=7), GH-deficient patients, coronary artery disease patients (n=24), and severe cardiomyopathy patients (n=13). The defining practical limitation is pronounced tachyphylaxis: GH response attenuates 50 to 75% within weeks of daily use. Phase 2 development reached for GH deficiency and congestive heart failure but was discontinued in 2005 for commercial rather than safety reasons.

🔒

Full Profile: Premium Members Only

The complete Hexarelin profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use